Table 3.
Demographic and Clinical Characteristics of Patients in the Chemotherapy and Enzyme-Treatment Groups
| Variable | Treatment |
P | |
|---|---|---|---|
| Chemotherapy (n = 23) | Enzyme Treatment (n = 32) | ||
| Sex | .22 | ||
| Male | |||
| No. | 16 | 17 | |
| % | 70 | 53.1 | |
| Female | |||
| No. | 7 | 15 | |
| % | 30 | 46.9 | |
| Stage | .54 | ||
| II to III | |||
| No. | 9 | 10 | |
| % | 39.1 | 31.3 | |
| IV | |||
| No. | 14 | 22 | |
| % | 60.9 | 68.7 | |
| ECOG performance status | |||
| 0 | |||
| No. | 4 | 11 | |
| % | 17 | 34.4 | |
| 1 | |||
| No. | 17 | 19 | |
| % | 74 | 59.4 | |
| 2 | |||
| No. | 2 | 2 | |
| % | 9 | 6.2 | |
| Age, years | .98 | ||
| Mean | 58.44 | 58.47 | |
| SD | 9.38 | 9.23 | |
| Weight, kg | .93 | ||
| Mean | 70.88 | 71.22 | |
| SD | 14.37 | 12.05 | |
| Total bilirubin, mg/dL | .01 | ||
| Mean | 1.04 | 0.63 | |
| SD | 0.64 | 0.35 | |
| Alkaline phosphatase, U/L | .86 | ||
| Mean | 126.09 | 121.31 | |
| SD | 82.20 | 105.59 | |
| WBC, 109/L | .18 | ||
| Mean | 7.78 | 6.81 | |
| SD | 2.73 | 2.45 | |
| Hematocrit, % | .92 | ||
| Mean | 37.08 | 37.32 | |
| SD | 7.03 | 9.39 | |
| Platelet, 109/L | .53 | ||
| Mean | 245.91 | 230.28 | |
| SD | 110.86 | 73.71 | |
| BUN, mg/dL | .35 | ||
| Mean | 14.78 | 13.44 | |
| SD | 4.48 | 6.11 | |
| Creatinine, mg/dL | .24 | ||
| Mean | 1.21 | 0.84 | |
| SD | 1.73 | 0.22 | |
| Albumin, g/dl | .04 | ||
| Mean | 4.27 | 4.00 | |
| SD | 0.52 | 0.47 | |
| AST, U/L | .80 | ||
| Mean | 25.09 | 26 | |
| SD | 15.16 | 10.43 | |
| ALT, U/L | .41 | ||
| Mean | 38.26 | 31.43 | |
| SD | 35.24 | 18.60 | |
| CA19-9, U/mL | .9219 | ||
| Mean | 9,117 | 9,700 | |
| SD | 15,945 | 20,347 | |
| Total QOL score | .42 | ||
| Mean | 107.31 | 111.69 | |
| SD | 18.42 | 15.45 | |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; SD, standard deviation; BUN, blood urea nitrogen; QOL, quality of life.